Compare LMFA & CLDI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LMFA | CLDI |
|---|---|---|
| Founded | 2008 | 2014 |
| Country | United States | United States |
| Employees | 19 | 29 |
| Industry | Finance: Consumer Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.8M | 3.4M |
| IPO Year | 2015 | N/A |
| Metric | LMFA | CLDI |
|---|---|---|
| Price | $0.15 | $0.16 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $5.00 | N/A |
| AVG Volume (30 Days) | 1.2M | ★ 2.6M |
| Earning Date | 05-15-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 34.66 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $8,844,733.00 | N/A |
| Revenue This Year | $4.38 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.12 | $0.12 |
| 52 Week High | $5.14 | $7.32 |
| Indicator | LMFA | CLDI |
|---|---|---|
| Relative Strength Index (RSI) | 29.50 | 43.63 |
| Support Level | N/A | $0.16 |
| Resistance Level | $0.27 | $0.18 |
| Average True Range (ATR) | 0.02 | 0.02 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 16.20 | 61.79 |
LM Funding America Inc is a financial services company. The company provides funding to nonprofit community associations located in the state of Florida and to nonprofit community associations in the states of Washington and Colorado. Its products include Original Product and New Neighbor Guaranty. Its original product offering consists of providing funding to Associations by purchasing their rights under delinquent accounts that are selected by the Associations arising from unpaid Association assessments. It currently has two lines of business recently commenced cryptocurrency mining business and historical specialty finance business. The Company has two operating segments: Specialty Finance and Mining and Treasury Operations.
Calidi Biotherapeutics Inc is a biotechnology company pioneering the development of targeted therapies with the potential to deliver genetic medicines to distal sites of disease. The company's proprietary RedTail platform features an engineered enveloped oncolytic virus designed for systemic delivery and targeting of metastatic sites. Its technology is intended to shield the virus from immune clearance, allowing virotherapy to effectively reach tumor sites, induce tumor lysis, and deliver potent genetic medicine(s) to metastatic locations. Its product candidates include The RedTail for Metastatic Solid Tumors, CLD-101 for Recurrent HGG; CLD-201 for Solid Tumors, and CLD-101 (NeuroNova) for Newly Diagnosed High Grade Glioma.